# of Displayed Technologies: 9 / 9

Applied Category Filter (Click To Remove): Drugs/Pharmaceuticals


Categories

Development of novel furano-parthenolides for human leukemia treatment
TS-038998 — Parthenolide analogues derived from plants could be effective in treating leukemia or supplementing other treatments.
The American Cancer Society estimates that in 2017 there will be about 1,688,780 new cancer cases diagnosed and 600,920 cancer deaths in the United States. Chemotherapy has improved, but further development is needed to improve the efficacy of this treatment, and cancers can develop multidrug resi…
  • College: College of Pharmacy
  • Inventors: Ren, Yulin
  • Licensing Officer: Flammang, Ann Marie

Novel Small-Molecule Integrin-linked Kinase/Phosphoinositide-dependent Protein Kinase-2 Inhibitors
TS-037647 — A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.
The Akt signaling pathway is responsible for apoptosis, cell proliferation, and metabolism. In tumor cells, this pathway is up-regulated and aids in promoting cancer cell survival. Complete activation of Akt pathway requires phosphorylation at two amino-acid residues, which are phosporylated by se…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Kulp, Samuel; Lee, Su-Lin
  • Licensing Officer: Paschall, Christopher

Small-Molecule Cyclin D1 Ablative Agents for Breast Cancer Therapy
TS-015102 — A new class of small-molecule cyclin D1 ablative agents based on troglitazone (TG) that repress intracellular cyclin D1 levels.
Cyclin D1 represents an important downstream effector of diverse proliferative and transforming signaling pathways. In mammary cells, transcriptional activation of Cyclin D1 leads to G1/S phase progression and increased proliferation. Cyclin D1 overexpression has been implicated in oncogene-induce…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Huang, Jui-Wen
  • Licensing Officer: Paschall, Christopher

New Energy Restriction-Mimetic Agents for Cancer Treatment
TS-015097 — Development of thiazolidinedione (TZD), OSU-CG12, as a novel energy restriction-mimetic agent for cancer therapy and chemo-prevention.
Cancer cells shift cellular metabolism to aerobic glycolysis to gain growth advantages in microenvironments, which has raised interest in therapies that exploit the response of malignant versus normal cells to glycolytic inhibition. Chronic energy restriction is difficult to implement as a chemo-p…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih
  • Licensing Officer: Paschall, Christopher

DNA Methylation Inhibitors
TS-015096 — A set of novel DNA methylation inhibitors that reduce DNA methylation by small molecule agents.
Substantial evidence indicates that DNA methylation-mediated silencing of tumor suppressor genes is a mechanism for the pathogenesis of cancer and many other diseases. Thus, small-molecule agents that target DNA methylation are considered a therapeutically relevant strategy for cancer treatment. T…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Hsiao, Shu-Huei; Leu, Yu-Wei; Shaw, Arthur
  • Licensing Officer: Paschall, Christopher

Estrogen Receptor Beta Agonist Compounds
TS-015086 — Estrogen Receptor Beta Agonists for the treatment of breast, colon, and prostate cancers as well as inflammatory diseases.
There is a large emphasis on the need for novel and more effective cancer therapeutics, since there were nearly 600,000 cancer deaths in the United States in 2016 alone. One method for therapy of prostate, breast, and colon cancer that has been gaining traction is the targeting of estrogen recepto…
  • College: College of Pharmacy
  • Inventors: Tjarks, Werner; Bartunek, Petr; Sedlak, David
  • Licensing Officer: Rumpal, Nidhi

Small Molecule AR-Ablative Agents
TS-014842 — A new strategy for using androgen receptor ablative agents has been developed for prostate cancer therapy.
Hormone-refractory prostate cancer is incurable, and patients with this disease have few treatment options. Dysregulation of the androgen receptor (AR) is a hallmark of this incurable cancer. Molecular changes during cancer enhance AR sensitivity or permit AR activation by antiestrogen so that pro…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Wang, Dasheng; Yang, Jian
  • Licensing Officer: Paschall, Christopher

Novel Indole-3-Carbinol-Derived Antitumor Agents
TS-014815 — An anti-tumor agent developed from indol-3-carbinol, a naturally occurring phytochemical in cruciferous vegetables.
According to the Center for Disease Control and Prevention, cancer is the second leading cause of death in the US at approximately 600,000 deaths per year. In addition, the National Cancer Institute estimates that nearly 1.7 million cases of cancer are diagnosed each year. A report from U.S. News …
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Weng, Jing-ru
  • Licensing Officer: Paschall, Christopher

Novel Protein Kinase C Delta Activators
TS-014754 — A novel anti-cancer agent (OSU-2S) that is devoid of S1P1 receptor activity and is highly effective in suppressing hepatocellular carcinoma tumor growth in vivo.
The third leading cause of cancer death worldwide is hepatocellular carcinoma (HCC). Due to the rise in the incidence of hepatitis C virus infection, HCC is expected to increase in the United States. Many patients with HCC are not candidates for surgery because of the location or size of their tum…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Byrd, John; Kulp, Samuel; Muthusamy, Natarajan; Wang, Dasheng
  • Licensing Officer: Paschall, Christopher
PDF

Loading icon